Biogen Idec appointed Brian S. Posner to its board of directors. The company is facing a class action lawsuit with investors being notified of an impending deadline. Cuts in costs yielded a higher-than-expected profit, showing promise for the
Alzheimer's drug, Leqembi's launch.
Biogen and partner,
Sage, have finished filing for the
Zuranolone NDA targeted at
depression. Biogen and
Ionis released the
topline results from the phase 1/2 study of their investigative drug for Amyotrophic Lateral Sclerosis. Biogen's stock position was cut by Hennion & Walsh Asset Management while
shareholders are urged to contact Levi & Korsinsky to discuss their rights. Biogen acquired
HI-Bio to expand its rare disease pipeline. Despite issues with Medicare, the company's
profit exceeded expectations due to cost-cutting measures. The company completed the acquisition of
Reata Pharmaceuticals and acquired Biogen's BIIB131 for acute ischemic stroke. Biogen's
stock dipped compared to its competitors but then surged following an FDA delay on Eli Lily's Alzheimer's treatment. Forecasts are positive though the company reported a 30% shareholder loss.
Biogen BIIB News Analytics from Fri, 28 Jul 2023 07:00:00 GMT to Sun, 30 Jun 2024 11:45:22 GMT -
Rating 2
- Innovation 0
- Information 4
- Rumor -3
